Lipocine Starts Phase 3 BLOOM Study of Oral Brexanolone for Postpartum Depression

New Phase 3 Study Will Evaluate 48-Hour At-Home Treatment

Lipocine Inc. has announced the start of BLOOM, a new Phase 3 clinical trial evaluating LPCN 1154, an investigational oral formulation of brexanolone for postpartum depression (PPD).

The company expects to dose the first participant in early Q4 2026.

Lipocine is developing LPCN 1154 as a 48-hour treatment that could be taken at home. The company is studying the medicine with the goal of providing rapid symptom relief through a short oral treatment course.

LPCN 1154 is not currently approved by the U.S. Food and Drug Administration (FDA). Its effectiveness, safety and suitability for use at home will need to be established through clinical studies and regulatory review.

What Is Postpartum Depression?

Postpartum depression is a serious mental health condition that can develop after childbirth.

It can affect a person's mood, daily activities, relationships and ability to care for themselves or their baby. Symptoms may include persistent sadness, loss of interest, anxiety and, in some cases, thoughts of self-harm.

According to research from the U.S. Centers for Disease Control and Prevention (CDC), about 1 in 8 women with a recent live birth reported symptoms of postpartum depression.

Treatment can include psychotherapy and antidepressant medicines.

There is also an FDA-approved oral neuroactive steroid treatment, zuranolone, which is given as a 14-day course. Another treatment, intravenous brexanolone, was previously approved but its U.S. commercial approval was withdrawn at the sponsor's request effective April 14, 2025.

Lipocine Is Developing a Short Oral Treatment

LPCN 1154 is an investigational oral formulation of brexanolone.

Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid in the body. It works by modulating GABAA receptors, which are involved in signaling in the brain.

Lipocine is developing LPCN 1154 as a 48-hour oral treatment for postpartum depression.

The company believes that a short treatment that can potentially be taken at home could offer a practical option for women and families dealing with postpartum depression.

However, these potential benefits still need to be confirmed through clinical testing.

BLOOM Phase 3 Study Will Enroll About 120 Participants

The Brexanolone Lifting Outcomes of Moms, or BLOOM, study is expected to enroll approximately 120 participants with postpartum depression.

The study is being designed as an outpatient trial, meaning participants will not need to stay in a hospital simply to receive the investigational treatment.

The study builds on Lipocine's earlier Phase 3 clinical trial and incorporates changes based on feedback from the FDA and lessons learned from the previous study.

The earlier trial used the same 48-hour treatment approach that will be evaluated in BLOOM.

What Will Researchers Measure?

The main effectiveness measure in BLOOM will be the change in participants' depression symptoms.

Researchers will use the 17-item Hamilton Depression Rating Scale, commonly called HAM-D17, to measure depression severity.

The primary endpoint will look at the change from the participant's starting score at 60 hours after treatment begins.

In simple terms, researchers will compare depression scores before treatment with scores after the 48-hour treatment period to determine whether symptoms improve.

Earlier Phase 3 Trial Did Not Meet Its Main Endpoint

Lipocine's decision to conduct another Phase 3 study follows mixed findings from its previous trial.

The earlier Phase 3 study did not meet its primary endpoint when all participants included in the main analysis were considered.

However, the company later conducted exploratory post hoc analyses.

These analyses identified unusual results concentrated at one clinical trial site that enrolled a large number of participants.

According to Lipocine, blood testing showed that approximately 40% of participants who received LPCN 1154 at that site did not have detectable study drug in their blood samples.

This raised questions about whether the treatment had been properly received or whether there were other site-related issues that could have affected the study results.

Exploratory Findings Suggested Symptom Improvement

When the data from the site in question were excluded, analyses suggested rapid and sustained improvement in depression symptoms among participants receiving LPCN 1154.

However, Lipocine has made clear that these findings are exploratory.

They are based on analyses performed after the original study and are not considered confirmatory evidence that LPCN 1154 is effective.

The new BLOOM study is intended to evaluate the treatment prospectively under stronger site and data-quality controls.

BLOOM Includes Stronger Site Quality Controls

Lipocine has made several changes to the design and operation of BLOOM.

The company plans to regularly review the patient populations at participating sites and use third-party support for site selection.

The study will also include geographic diversity and participation from academic centres.

Sites with significant operational or data-quality concerns from the previous experience will not be selected.

These measures are intended to reduce the risk of problems that could affect the reliability of the trial data.

Study Will Also Try to Reduce Placebo Response

The BLOOM protocol includes several measures designed to reduce the potential impact of placebo response.

The study will use fewer rating scales and assessments compared with some traditional trial designs.

Participants will also have less frequent contact with site staff.

Screening and eligibility assessments will include centralized ratings, while information about study procedures and assessments will be standardized for participants.

These changes are intended to create a more consistent trial environment and improve the quality of the data.

Prespecified Analyses Will Examine Important Trial Data

BLOOM will also include planned sensitivity analyses.

These analyses will specifically address potential outlier sites and pharmacokinetic data.

Pharmacokinetics, or PK, refers to what happens to a medicine inside the body, including how much of the drug reaches the bloodstream and how long it remains there.

Including these analyses in advance gives researchers a planned way to examine unusual results and understand how they may affect the study findings.

Earlier Study Showed Encouraging Safety Findings

The previous Phase 3 trial also provided safety information that Lipocine considers encouraging.

The company reported that no treatment-related severe or serious adverse events were observed.

There were also no reported cases of excessive sedation or loss of consciousness.

No participants discontinued treatment because of these safety concerns.

These findings will continue to be monitored in the BLOOM study as researchers evaluate LPCN 1154 in a new group of participants.

Lipocine Sees Potential in At-Home Treatment

Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine, said the company believes a 48-hour oral treatment that can be taken at home could change how women and families manage postpartum depression.

He said BLOOM is designed to build on earlier clinical findings and FDA feedback while focusing on generating the evidence needed for a potential regulatory submission.

The company said its priorities for the new study include careful trial execution, clinically meaningful results and controlled use of its financial resources.

Lipocine Expects to Fund BLOOM With Existing Resources

Lipocine also provided an update on its financial position and expected spending during the trial.

The company expects to use approximately $1 million per month on average during study execution, including costs related to BLOOM.

As of June 30, 2026, Lipocine reported $23.3 million in unrestricted cash, cash equivalents and marketable investment securities.

The company believes its current financial and operational resources are sufficient to carry out the BLOOM study under its current operating plan.

However, Lipocine noted that these estimates depend on factors such as how long the study takes, enrollment, costs and other operating requirements.

The company also said its current resources are not being presented as sufficient to fund regulatory approval or commercialization.

What Happens After BLOOM?

The immediate focus will be on enrolling participants and starting treatment in the Phase 3 BLOOM study.

The company will collect efficacy, safety and other clinical data throughout the trial.

If the study produces supportive results, Lipocine could use the data as part of a potential New Drug Application under the FDA's 505(b)(2) regulatory pathway.

Any future regulatory submission and approval will depend on the complete clinical data package and FDA review.

Lipocine's Broader Development Pipeline

LPCN 1154 is one of several programs in Lipocine's development pipeline.

The company is also developing LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 2401 for obesity management, LPCN 1148 for symptoms associated with liver cirrhosis and LPCN 1107 for prevention of preterm birth.

Lipocine's TLANDO, an oral prodrug of testosterone containing testosterone undecanoate, is already FDA-approved for adult men with hypogonadism associated with testosterone deficiency.

The company uses its proprietary oral drug-delivery technology to develop oral treatments for different medical conditions.